Alamar Biosciences, Inc. Common Stock (ALMR) is a publicly traded the market company. As of May 21, 2026, ALMR trades at $20.16 with a market cap of $1.45B and a P/E ratio of 0.00. ALMR moved -1.51% today. Year to date, ALMR is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $20.02 to $27.20. Analyst consensus is strong buy with an average price target of $30.00. Rallies surfaces ALMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alamar Biosciences Q1 Revenue Nearly Doubles to $26M, Margin Hits 56%: Alamar Biosciences posted Q1 2026 revenue of $26.0M, up 99% year-over-year, driven by a 78% rise in instrument sales to $7.4M and 178% growth in consumable revenue to $14.0M. Gross margin improved to 56%, while cash and equivalents totaled $69.5M following its April IPO which raised approximately $220M.
| Metric | Value |
|---|---|
| Price | $20.16 |
| Market Cap | $1.45B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.20 |
| 52-Week Low | $20.02 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover ALMR: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.00.